$MBIO News

Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio shares are trading higher after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.

Mustang Bio shares are trading higher after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.

Mustang Bio Granted FDA Orphan Drug Designation For MB-101 In Astrocytomas And Glioblastoma

Mustang Bio shares are trading higher after the company announced it received FDA Orphan Drug designation status for MB-101.

Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma

Mustang Bio Designated Orphan Designation Status For "an autologous ex vivo expanded cluster of differentiation 62-enriched naive and memory T-cell investigational product that has been genetically modified using a self-inactivating lentiviral vector to express an IL13Ralpha2-targeted, hinge-optimized, 4-1BB-costimulatory chimeric antigen receptor with a truncated CD19" For The Treatment Of Malignant Glioma

Mustang Bio Regains Nasdaq Compliance

Mustang Bio shares are trading lower after the company announced the exit of its lease for the Massachusetts facility.

Mustang Bio Announces Sale Of Fixed Assets And Exit Of Facility For $1M

Mustang Bio shares are trading higher after the company announced it regained compliance with Nasdaq regarding its minimum bid price requirements.

Mustang Bio Regains Compliance with Nasdaq

Mustang Bio Reports Pricing Of $8M Public Offering

Mustang Bio shares are trading lower after the company announced a public offering of 2.65 million shares of Series C-1 and C-2 warrants.

Mustang Bio Priced Its Public Offering Of 2.65M Shares, Series C-1 Warrants To Purchase Up To 2.65M Shares And Series C-2 Warrants To Purchase Up To 2.65M Shares At A Combined Public Offering Price Of $3.01 Per Share

Mustang Bio Announces Reverse Stock Split

Mustang Bio shares are trading lower after the company announced a 1-for-50 reverse stock split.

Mustang Bio Announces 1-For-50 Reverse Stock Split, Expects Its Common Stock To Begin Trading On A Split-Adjusted Basis On January 16, 2025

Mustang Bio Granted Extension By Nasdaq Hearings Panel To Meet Listing Criteria; Must Comply With $1.00 Bid Price By Jan 31, 2025, And $2.5M Stockholders' Equity By Feb 18, 2025